Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
| ▸ | ADAM10 | O14672 | 1/20 | 0.32 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3266459 | 0.76 | MEN1 (0.51) | MEN1KMT2APOLBTDP1NOTUM | |
| SCHEMBL3246762 | 0.74 | CYP3A4 (0.41) | MEN1KMT2ANOTUMALDH1A1LMNA | |
| SCHEMBL3246780 | 0.74 | CYP3A4 (0.41) | MEN1KMT2ANOTUMALDH1A1LMNA | |
| SCHEMBL3245972 | 0.69 | GAA (0.49) | MEN1KMT2ABLMKEAP1NFE2L2 | |
| SCHEMBL3241251 | 0.65 | NOTUM (0.41) | MEN1KMT2ANOTUM | |
| SCHEMBL3238530 | 0.64 | NOTUM (0.38) | MEN1KMT2ANOTUMALDH1A1MAPT | |
| SCHEMBL16579321 | 0.62 | MEN1 (0.50) | MEN1KMT2ABLMADAM10ERBB2 | |
| SCHEMBL4633137 | 0.62 | NOTUM (0.38) | MEN1KMT2ANOTUMLMNA | |
| SCHEMBL29618969 | 0.62 | NOTUM (0.53) | MEN1KMT2ANOTUMALDH1A1LMNA | |
| SCHEMBL29618970 | 0.62 | NOTUM (0.53) | MEN1KMT2ANOTUMALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2102204-B1 | NEW AMINOPYRROLO[1,2- A]INDOLE ET AMINOPYRIDAZINO[1,6-A]INDOLE DERIVATIVES, METHOD FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | SERVIER LAB (FR) | 2010-05-05 | — | — | EP | disclosed |
| US-20090298813-A1 | USE OF NEUROPROTECTIVE COMPOUNDS IN OBTAINING MEDICAMENTS INTENDED FOR THE TREATMENT OF NEURODEGENERATING DISEASES | LES LABORATOIRES SERVIER (FR) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298813-A1 | USE OF NEUROPROTECTIVE COMPOUNDS IN OBTAINING MEDICAMENTS INTENDED FOR THE TREATMENT OF NEURODEGENERATING DISEASES | NLN, GAP43, SNCA | MEN1 3021/4885KMT2A 4227/4885BLM 3442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.